Truist Securities Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) and raised the price target from $40 to $42.
August 09, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained its Buy rating on Collegium Pharmaceutical and raised the price target from $40 to $42.
The raised price target and maintained Buy rating from Truist Securities are positive signals for investors, likely leading to a short-term increase in COLL's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100